Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Dalton Transactions (Cambridge, England : 2003)|November 6, 2008
Bisursodeoxycholate(ethylenediamine)platinum(II): a new autofluorescent compound. Cytotoxic activity and cell cycle analysis in ovarian and hematological cell linesMartín Pérez-Andrés, Juan J Benito, Emilio Rodríguez-Fernández, et al.
British Journal of Haematology|August 31, 2006
Impact of BCR/ABL gene expression on the proliferative rate of different subpopulations of haematopoietic cells in chronic myeloid leukaemiaDaniel Primo, Juan Flores, Sandra Quijano, et al.
British Journal of Haematology|February 21, 2006
Lineage involvement in chronic myeloid leukaemia: comparison between MBCR/ABL and mBCR/ABL casesDaniel Primo, Maria Luz Sanchez, Ana Belén Espinosa, et al.
SLAS Technology|March 26, 2017
Drug Discovery Testing Compounds in Patient Samples by Automated Flow CytometryPilar Hernández, Julián Gorrochategui, Daniel Primo, et al.
American Journal of Clinical Pathology|December 16, 2003
Her-2/neu gene amplification in familial vs sporadic breast cancer. Impact on the behavior of the diseaseAna B Espinosa, Maria D Tabernero, Maria C García-Macías, et al.
Haematologica|December 15, 2018
Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasmsAlicia Arenas Cortés, Rosa Ayala Diaz, Pilar Hernández-Campo, et al.
Blood Advances|July 26, 2022
Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15Rafael Alonso Fernandez, Jessica Encinas Mayoral, Laetitia Pierre-Louis, et al.
Blood|June 4, 2026
PKMYT1 is a Targetable Vulnerability in del(17p) High-Risk Multiple MyelomaAnaïs Schavgoulidze, Jian Cui, Jessica Encinas, et al.
Oncotarget|June 15, 2018
A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemiaDaniel Primo, Lydia Scarfò, Aliki Xochelli, et al.
Journal of Hematology & Oncology|June 22, 2017
Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repairAna-Alicia López-Iglesias, Ana B Herrero, Marta Chesi, et al.
Pageof 2